Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer’s disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records of over 1.7 million US adults with T2D, focusing on dementia diagnoses over three years. Semaglutide showed a stronger protective effect against vascular dementia than insulin, metformin, and older glucagon-like peptide 1 receptor agonists. The risk reduction was more pronounced in younger adults. The study suggests semaglutide’s potential in reducing dementia-related medication prescriptions. The study highlights the need for further research to establish causal relationships and understand underlying mechanisms. The study was funded by the National Institute on Aging and the National Center for Advancing Translational Sciences.

From: Medscape